Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis
Open Access
- 21 September 2023
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (1) , 453-463
Abstract
Background: A greater than 1 mm tumour-free resection margin (R0 >1 mm) is a prognostic factor in upfront-resected pancreatic ductal adenocarcinoma. After neoadjuvant treatment (NAT); however, the prognostic impact of resection margin (R) status remains controversial. Methods: Randomised and non-randomised studies assessing the association of R status and survival in resected pancreatic ductal adenocarcinoma after NAT were sought by systematic searches of MEDLINE, Web of Science and CENTRAL. Hazard ratios (HR) and their corresponding 95% CI were collected to generate log HR using the inverse-variance method. Random-effects meta-analyses were performed and the results presented as weighted HR. Sensitivity and meta-regression analyses were conducted to account for different surgical procedures and varying length of follow-up, respectively. Results: Twenty-two studies with a total of 4929 patients were included. Based on univariable data, R0 greater than 1 mm was significantly associated with prolonged overall survival (OS) (HR 1.76, 95% CI 1.57–1.97; PPPP=0.0003). Results for R1 direct were comparable in the entire cohort; however, no prognostic impact was detected in sensitivity analysis including only partial pancreatoduodenectomies. Conclusion: After NAT, a tumour-free margin greater than 1 mm is independently associated with improved OS as well as DFS in patients undergoing surgical resection for pancreatic cancer.Keywords
This publication has 57 references indexed in Scilit:
- Pancreatic Adenocarcinoma: Treating a Systemic Disease With Systemic TherapyJNCI: Journal of the National Cancer Institute, 2014
- Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic CancerAnnals of Surgery, 2013
- Chapter 8: Meta-analysis of Test Performance When There is a “Gold Standard”Journal of General Internal Medicine, 2012
- Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal AdenocarcinomaAmerican Journal of Surgical Pathology, 2012
- Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiationCancer, 2011
- Post‐therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiationCancer, 2011
- Margin Clearance and Outcome in Resected Pancreatic CancerJournal of Clinical Oncology, 2009
- Most Pancreatic Cancer Resections are R1 ResectionsAnnals of Surgical Oncology, 2008
- Redefining the R1 resection in pancreatic cancerBritish Journal of Surgery, 2006
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002